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Introduction {#jdi12368-sec-0005}
============

Diabetes mellitus is the worldwide leading cause of chronic kidney disease (CKD). Diabetic nephropathy, one of the major diabetic complications, is the key attributor of end‐state kidney disease (ESRD)[1](#jdi12368-bib-0001){ref-type="ref"}. Besides the traditional risk factors including hypertension, poor glycemic control and levels of proteinuria, some new risk factors for the progression to ESRD, such as anemia, have been identified[2](#jdi12368-bib-0002){ref-type="ref"}.

Anemia is common among patients with type 2 diabetes, affecting approximately 15--32% of diabetes patients in population‐based cohorts, diabetic clinics as well as primary care clinics[3](#jdi12368-bib-0003){ref-type="ref"}, [4](#jdi12368-bib-0004){ref-type="ref"}, [5](#jdi12368-bib-0005){ref-type="ref"}. Increasing evidence shows that low hemoglobin level contributes to the progression of left‐ventricular hypertrophy, heart failure, all‐cause and cardiovascular mortality[6](#jdi12368-bib-0006){ref-type="ref"}, [7](#jdi12368-bib-0007){ref-type="ref"}. Similar effects of anemia on the development of nephropathy were also shown[8](#jdi12368-bib-0008){ref-type="ref"}, [9](#jdi12368-bib-0009){ref-type="ref"}. Anemia at baseline was shown as an independent risk factor for ESRD in several groups of high‐risk patients including diabetes[10](#jdi12368-bib-0010){ref-type="ref"}. In the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study, low hemoglobin level at baseline increased the risk of progression of nephropathy in type 2 diabetes patients[11](#jdi12368-bib-0011){ref-type="ref"}. However, correction of anemia failed to show any beneficial effect in alleviating kidney disease progression. Both the Correction of Hemogloblin and Outcomes in Renal Insufficiency study and the Anemia Correction in Diabetes study, two large clinical trials examining the effect of raising hemoglobin on the progression of kidney disease, did not show any significant benefit[12](#jdi12368-bib-0012){ref-type="ref"}, [13](#jdi12368-bib-0013){ref-type="ref"}. Most recently, the Trial to Reduce Cardiovascular Events with Aranesp Therapy also reported that treating anemia with darbepoetin alfa in patients with diabetes and CKD conferred no benefit in renal events or ESRD[14](#jdi12368-bib-0014){ref-type="ref"}. These findings led us to doubt the actual contribution of anemia on CKD progression, especially in diabetes patients.

Anemia has a close interaction with renal dysfunction in diabetes patients. Anemia is common in diabetes patients with nephropathy, and its severity worsens with more advanced stage of CKD and proteinuria[2](#jdi12368-bib-0002){ref-type="ref"}. At the same time, low estimated glomerular filtration rate (eGFR) and high urine albumin are two major risk factors for ESRD with strong predictive powers[15](#jdi12368-bib-0015){ref-type="ref"}. More proof is still awaited on the relationships among anemia, nephropathy and progression of renal disease. Furthermore, most of the studies in this field were carried out in Caucasian populations, whereas epidemiological studies have shown a considerable variation in both anemia and nephropathy in diabetes patients across different ethnicity[16](#jdi12368-bib-0016){ref-type="ref"}. The prevalence of diabetes is increasing dramatically in China[17](#jdi12368-bib-0017){ref-type="ref"}, [18](#jdi12368-bib-0018){ref-type="ref"}. In the present study, we tried to examine whether anemia is associated with an increased risk of renal disease progression in a cohort of Chinese type 2 diabetes patients. We have also evaluated whether this risk is modified by eGFR.

Materials and methods {#jdi12368-sec-0006}
=====================

The present longitudinal study was carried out within the frame of the Staged Diabetes Targeting Management study, which began in 2006 as part of a continuous structured diabetes care program for outpatient diabetes management in Jiangsu Province Official Hospital, aiming to document all the risk factors, medical interventions, complications and clinical outcomes of diabetes patients in the real‐world practice. A modified European Implementation of Quality Management in Diabetes Care (DIABCARE) assessment of complications and risk factors[19](#jdi12368-bib-0019){ref-type="ref"} was carried out during the first visit when the patient was enrolled into the study. All patients were followed up according to the Staged Diabetes Management protocol adopted from the International Diabetes Center (Minneapolis, MN, USA)[20](#jdi12368-bib-0020){ref-type="ref"}, and the clinical information at each visit was recorded online ([www.chinasdtm.com](http://www.chinasdtm.com)). The study protocol has been approved by the ethical committee, Jiangsu Province Institute of Geriatrics, Nanjing, China. Written informed consent was obtained from all patients at the time of the first assessment to allow use of their data for research purposes.

Data in this analysis were collected from patients recruited in the period between January 2006 and December 2012, and all the follow‐up data were censored on 30 June 2013. A total of 2,802 diabetic patients were enrolled into the Staged Diabetes Targeting Management study. After excluding those who had a history of type 1 diabetes, cancer, hematological diseases, CKD of stage IV and V (eGFR \<30 mL/min/1.73 m^2^) at baseline, or incomplete data for key variables (hemoglobin and serum creatinine), we had the complete data from 1,645 patients for the final analysis.

Simple physical examinations including bodyweight, height and blood pressure measurement were carried out by the diabetes nurses. Body mass index was calculated by dividing weight (kg) by the square of height (m). Blood pressure was measured with a standard mercury manometer after at least 5 min of rest. Details on personal information, disease history and current use of medications were also obtained from all patients through interviews by the nurses.

Blood tests were carried out after an overnight fating for plasma glucose, lipid profiles, complete blood count, renal/liver functions and glycated hemoglobin (HbA~1c~). A spot urine specimen was collected for albumin‐to‐creatinine ratio. Fasting plasma glucose, total cholesterol, triglycerides, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol and serum creatinine were measured using a Hitachi 7060 automated analyzer (Hitachi Koko Co. Ltd., Hitachinaka City, Japan). HbA~1c~ was measured by Bio‐Rad Diamat high‐performance liquid chromatography analyzer (Bio‐Rad Labs., Brea, CA, USA). Spot urine albumin‐to‐creatinine ratio was measured with DCA 2000 (Bayer Corp., Elkhart, IN, USA).

Anemia was defined as hemoglobin concentrations \<120 g/L in women or \<130 g/L in men[21](#jdi12368-bib-0021){ref-type="ref"}. Estimated GFR was calculated using the abbreviated Modification of Diet in Renal Disease formula[22](#jdi12368-bib-0022){ref-type="ref"}: eGFR = 186 × (SCR × 0.011)^−1.154^ × (age)^−0.203^ × (0.742 if female), where SCR is serum creatinine expressed as μmol/L. Progression of renal disease was defined as: (i) death as a result of diabetes with renal manifestation or renal failure; (ii) permanent need for dialysis or renal transplantation; or (iii) doubling of baseline serum creatinine level. The decline rate of eGFR per year was calculated: (eGFR at baseline − eGFR at last follow up) / years of follow up.

Statistical analysis was carried out using the [spss]{.smallcaps} software (version 15.0; SPSS, Chicago, IL, USA). All data are expressed as mean ± standard deviation, median (interquartile range) or percentage, where appropriate. Rates were compared using the χ^2^‐test and means using Student\'s *t*‐test between the two groups with or without anemia at baseline. Variables not normally distributed were analyzed using non‐parametric tests (Mann--Whitney *U*‐test). Cox hazards regression analysis was used to study the association of anemia and eGFR with renal disease progression. All the variables included for multivariate Cox regression models are described in the Results section.

Results {#jdi12368-sec-0007}
=======

Of the 1,645 participants, there were 1,055 (64.1%) men and 590 (35.9%) women. Their mean age was 64.2 ± 11.9 years (median 66 years, range 30--89 years). Anemia defined by the World Health Organization was present in 21.3% (*n* = 350) of the whole cohort. Table [1](#jdi12368-tbl-0001){ref-type="table-wrap"} summarizes the baseline characteristics of patients grouped by anemia status. Compared with those without anemia, patients with anemia had a lower eGFR, but higher albuminuria, and a longer duration of diabetes. As expected, the hemoglobin level was notably lower in patients with anemia, both in males and females. There were more older age patients in this group, and they were more likely to be treated with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.

###### 

Baseline characteristics of the 1,645 Chinese type 2 diabetes patients with or anemia

                                                                     No anemia (*n* = 1,295)   Anemia (*n* = 350)   *P‐*value          
  ------------------------------------------------------------------ ------------------------- -------------------- ----------- ------ ------------------------------------------------
  Male (%)[†](#jdi12368-note-0001){ref-type="fn"}                    64.2                      --                   64.0        --     0.953[§](#jdi12368-note-0002){ref-type="fn"}
  Age (years)                                                        63.0                      11.8                 68.6        11.1   \<0.001
  Diabetes duration (years)[‡](#jdi12368-note-0001){ref-type="fn"}   7.0                       8.0                  9.0         11.0   \<0.001[¶](#jdi12368-note-0002){ref-type="fn"}
  BMI (kg/m^2^)                                                      24.7                      3.0                  24.1        3.5    0.001
  Systolic BP (mmHg)                                                 127.5                     13.9                 129.7       15.0   0.012
  Fasting PG (mmol/L)                                                7.8                       3.1                  7.4         2.6    0.044
  HbA~1c~ (%)                                                        7.8                       1.9                  7.8         1.9    0.478
  Total cholesterol (mmol/L)                                         4.86                      1.30                 4.65        1.07   0.008
  Triglyceride (mmol/L)                                              1.82                      1.40                 1.52        0.94   \<0.001
  HDL‐C (mmol/L)                                                     1.18                      0.32                 1.18        0.32   0.852
  LDL‐C (mmol/L)                                                     2.91                      0.79                 2.76        0.84   0.004
  Hemoglobin (g/L)                                                   142.8                     11.0                 115.4       10.7   \<0.001
  Male                                                               146.2                     9.6                  118.2       11.3   \<0.001
  Female                                                             136.5                     10.6                 110.5       7.3    \<0.001
  Hematocrit (L/L)                                                   0.40                      0.04                 0.34        0.04   \<0.001
  Red cell count (10^12^/L)                                          4.55                      0.44                 3.84        0.50   \<0.001
  eGFR (mL/min/1.73 m^2^)                                            97.9                      27.8                 89.7        29.5   \<0.001
  ACR (mg/g)[‡](#jdi12368-note-0001){ref-type="fn"}                  11.3                      19.0                 15.0        25.6   \<0.001[¶](#jdi12368-note-0002){ref-type="fn"}
  ACEI or ARB treatment (%)[†](#jdi12368-note-0001){ref-type="fn"}   32.9                      --                   44.6        --     \<0.001[§](#jdi12368-note-0002){ref-type="fn"}

Data were expressed as mean ± standard deviation (SD), ^†^percentage or ^‡^median and interquartile range.

§The χ2‐test and ¶non‐parametric Mann--Whitney *U*‐test. ACEI, angiotensin converting enzyme inhibitor; ACR, albumin‐to‐creatinine ratio; ARB, angiotensin II receptor blocker; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL‐c, high‐density lipoprotein cholesterol; IQR, interquartile range; LDL‐c, low‐density lipoprotein cholesterol; PG, plasma glucose.
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The median follow up was 49 months (interquartile range 28--62 months). During the follow‐up period, 49 patients (2.98%) died, all of them were evaluated for the progression of renal disease using the last available data in the diabetic clinic visits. In total, 37 (2.25%) patients had a doubled serum creatinine compared with their baseline levels, including those nine patients who received long‐term renal dialysis. All of these 37 patients met the definition of renal disease progression as described above, 14 (4.00%) in the group with anemia and 23 (1.78%) in the group without anemia. Incidence of renal disease progression was strongly associated with both anemia (*P* \< 0.013) and renal function (*P* \< 0.001). There were obvious additive effects of anemia and worsening renal function on renal disease progression. The incidence of renal disease progression in patients with eGFR more than 90 mL/min/1.73 m^2^ and without anemia was 1.5%. However, it was 21.4% in those patients with anemia and eGFR less than 60 mL/min/1.73 m^2^ at baseline (*P *\< 0.001).

Multivariate cox regression analysis showed that baseline anemia was a strong predictor of renal disease progression (Table [2](#jdi12368-tbl-0002){ref-type="table-wrap"}, line 1). As illustrated, anemia was associated with a high risk of renal disease progression even after adjustment for age and sex (Table [2](#jdi12368-tbl-0002){ref-type="table-wrap"}, line 2). However, when eGFR was included for the analysis, anemia lost its significance (Table [2](#jdi12368-tbl-0002){ref-type="table-wrap"}, line 3 and 4). Anemia was also removed from the model after adjustment for traditional predictors for ESRD, such as age, systolic blood pressure, eGFR and blood glucose level. In the final multiple adjusted model, diabetes duration, eGFR and HbA~1c~ were independent predictors of renal disease progression (Table [2](#jdi12368-tbl-0002){ref-type="table-wrap"}, line 5, 6 and 7).

###### 

Multivariate Cox regression for renal disease progression by baseline characteristics

                                 Wald    SEM     HR (95% CI)            *P*‐value
  ------------------------------ ------- ------- ---------------------- -----------
  Anemia Crude                   7.974   0.340   2.609 (1.341--5.077)   0.005
  Adjusted for age, sex          4.583   0.362   2.170 (1.068--4.410)   0.032
  Adjusted for age, sex, eGFR    3.297   0.368   1.952 (0.948--4.016)   0.069
  Multiple adjusted              2.095   0.393   1.767 (0.817--3.821)   0.148
  Diabetic duration (+1 month)   4.830   0.002   1.004 (1.000--1.008)   0.028
  eGFR (+1 mL/min/1.73 m^2^)     4.582   0.005   1.012 (1.001--1.023)   0.032
  HbA~1c~ (+1%)                  4.900   0.090   1.221 (1.023--1.457)   0.027

Only anemia and statistically significant variables were presented in the table. Other variables included in the model were: age (year), sex (male vs female), body mass index (kg/m^2^), systolic blood pressure (mmHg), low‐density lipoprotein cholesterol level (mmol/L) and use of angiotensin converting enzyme inhibitor or angiotensin II receptor blocker. CI, confidence interval; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HR, hazard ratio; SEM, standard error of the mean.
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Based on anemia being strongly associated with renal dysfunction in diabetes patients, interaction analysis between anemia and eGFR was carried out in subgroups divided by eGFR ≥90 mL/min/1.73 m^2^, 90 \> eGFR ≥ 60 mL/min/1.73 m^2^ or 60 \> eGFR ≥ 30 mL/min/1.73 m^2^. As shown in Table [3](#jdi12368-tbl-0003){ref-type="table-wrap"}, HR of baseline anemia was significantly higher in patients with CKD 3 (eGFR \<60 mL/min/1.73 m^2^) compared with the rest of the diabetic patients (hazard ratio 4.816 vs 0.034 and 1.876, *P* \< 0.001), but anemia failed to predict renal disease progression in all three subgroups in a full adjusted regression model. Consistent with the aforementioned results, there was no difference between the decline rate of eGFR per year between patients with or without anemia, as shown by non‐parameter Mann--Whitney *U*‐test (Figure [1](#jdi12368-fig-0001){ref-type="fig"}). In addition, the decline rate of eGFR was not correlated with hemoglobin level in both males (*r* = −0.028, *P* = 0.400) and females (*r* = −0.086, *P* = 0.060).

###### 

Hazard ratio of baseline anemia for renal disease progression

  eGFR                      *n*     Crude HR               *P*‐value (95% CI)   Multiple adjusted HR[a](#jdi12368-note-0004){ref-type="fn"}   *P*‐value (95% CI)[a](#jdi12368-note-0004){ref-type="fn"}
  ------------------------- ------- ---------------------- -------------------- ------------------------------------------------------------- -----------------------------------------------------------
  All                       1,644   2.609 (1.341--5.077)   0.005                1.767 (0.817--3.821)                                          0.148
  ≥90 mL/min/1.73 m^2^      688     1.876 (0.594--5.922)   0.283                1.202 (0.226--6.388)                                          0.829
  60--90 mL/min/1.73 m^2^   576     0.034 (0.001--144.1)   0.428                0.001 (0.000--3464)                                           0.969
  \<60 mL/min/1.73 m^2^     112     4.816 (1.457--15.91)   0.010                1.609 (0.244--10.63)                                          0.621

Multiple adjusted for age, sex, diabetic duration, body mass index, glycated hemoglobin, low‐density lipoprotein cholesterol level, systolic blood pressure, estimated glomerular filtration rate (eGFR) and use of angiotensin converting enzyme inhibitor or angiotensin II receptor blocker. CI, confidence interval; HR, hazard ratio.
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![Distribution of the decline rate of estimated glomerular filtration rate (eGFR) in patients with or without anemia. Differences between groups were compared by non‐parametric Mann--Whitney *U*‐test.](JDI-7-042-g001){#jdi12368-fig-0001}

Discussion {#jdi12368-sec-0008}
==========

This single‐center longitudinal study described the rate of anemia, and the association between anemia and renal disease progression in a clinic‐based cohort of Chinese type 2 diabetes patients. More than 20% of the study populations were found to have anemia, and these patients had a higher risk of renal disease progression defined as ESRD or doubling of baseline serum creatinine, than those with normal hemoglobin. However, anemia had a significant interaction with baseline eGFR, and seemed to lose its significance as an independent risk factor for renal disease progression after adjusting for eGFR. Only HbA~1c~, eGFR and diabetes duration at baseline independently predicted renal disease progression in the present study.

Anemia has shown to be a predictor for ESRD or renal disease progression in most[9](#jdi12368-bib-0009){ref-type="ref"}, [10](#jdi12368-bib-0010){ref-type="ref"}, [23](#jdi12368-bib-0023){ref-type="ref"}, but not all, studies[24](#jdi12368-bib-0024){ref-type="ref"}. In the Multiple Risk Factor Intervention Trial involving middle‐aged men without significant kidney disease, there was no association between baseline hematocrit and development of ESRD after a follow up of 25 years[24](#jdi12368-bib-0024){ref-type="ref"}. Bansal *et al*. also found that anemia was associated with an increased risk for a doubling of serum creatinine in subjects with baseline CKD, but not in those without CKD[25](#jdi12368-bib-0025){ref-type="ref"}. In addition, Rossing *et al*. also reported that baseline hemoglobin did not correlate to the subsequent decline rate of eGFR[26](#jdi12368-bib-0026){ref-type="ref"}. In diabetes patients, although many studies showed that anemia was an independent risk factor for ESRD or renal disease progression, few of them[9](#jdi12368-bib-0009){ref-type="ref"}, [10](#jdi12368-bib-0010){ref-type="ref"}, [23](#jdi12368-bib-0023){ref-type="ref"} analyzed the interaction between anemia and eGFR.

The present data showed that baseline anemia was a risk factor for renal disease progression, but lost its significance after adjustment for eGFR. This was probably because of the strong interaction between anemia and eGFR in our population. Impaired renal function is an independent predictor for renal disease progression, and it is closely associated with anemia. As anemia often develops as a consequence of CKD, those patients with lower eGFR are likely to have lower hemoglobin concentrations and have higher risks to reach the definition of renal disease progression. Thus, low hemoglobin could provide some information on the severity of CKD, but anemia itself does not have a strong direct effect on the development of CKD. In fact, the rates of decline in eGFR were not different between patients with or without anemia in the present study. This might explain why anemia seems to be a risk factor for renal disease progression only when the baseline eGFR is not adjusted for. Similarly, Waldum *et al*. found that baseline anemia is not a predictor of all‐cause mortality in outpatients with severe renal dysfunction[27](#jdi12368-bib-0027){ref-type="ref"}. However, it is also possible that there are other confounding factors, such as erythropoietic stress[28](#jdi12368-bib-0028){ref-type="ref"}, existing in these patients. As we had no information on erythropoietin in the present study, this possibility remains to be established.

Anemia was a common finding in the present study, affecting approximately 21.3% of the diabetic patients in this population. Given most patients in this study were with normal or near normal renal function, it is not known why these patients had a high risk of anemia. In a cross‐sectional survey, the prevalence of anemia was also found to be high in diabetic patients, even in those with preserved renal function[5](#jdi12368-bib-0005){ref-type="ref"}, and the authors discussed the possibilities that some factors, such as iron stores, albuminuria and hyperglycemia, could contribute to anemia in diabetes[5](#jdi12368-bib-0005){ref-type="ref"}. Similar factors might also contribute to the high rate of anemia in this cohort of diabetic patients. In addition, some previous studies have shown a correlation between polyneuropathy and development of anemia in diabetes[29](#jdi12368-bib-0029){ref-type="ref"}. Because the average diabetes duration of the patients in the present study is more than 7 years, the potential diabetic neuropathy of these patients could also account for the high incidence of anemia, especially in those patients with preserved renal function.

It should be pointed out that the present study had several limitations. First, just 1645 patients from the original database were included in the analysis. Many patients were excluded because of lack of availability of serum creatinine and full blood count data. This situation reflects the shortage of our database establishment. Although the outpatient management system in China, in general, is still relatively immature, we are keen to make efforts to improve our skills and experience in managing the Staged Diabetes Management protocol[20](#jdi12368-bib-0020){ref-type="ref"}. Second, given the limited number of events, it might difficult to definitely answer the question of whether anemia is associated with an increased risk of renal disease progression. More renal complications are expected to occur with a longer follow‐up time. Nevertheless, the sample scale and the event rates that occurred in the present study should be statistically sufficient for the analysis. Third, the cohort could contain patients who are more health conscious and pay better adherence to treatments. Indeed, relatively good blood pressure (Table [1](#jdi12368-tbl-0001){ref-type="table-wrap"}), as well as relative low incidence of ESRD during the follow‐up period was observed in this cohort. Fourth, patients receiving erythropoiesis‐stimulating agents (ESA) are probably included in this population, but we did not have the information. However, we believe that the usage rate of ESA should be low in our population, because ESA is mostly prescribed to patients with ESRD in China. In the current study, the baseline hemoglobin level of patients with anemia was 115.4 g/L, which is within the target level recommended by recent studies[14](#jdi12368-bib-0014){ref-type="ref"}. This might be caused by anemia being defined as hemoglobin concentrations less than 120 g/L in women or 130 g/L in men in the present study. In addition, ESA‐related clinical trials failed to show beneficial effects on renal disease progression as aforementioned. Thus, use of ESA might have little effect on the present results. Last, but not least, the present study was carried out in a single urban hospital in an ethnically homogenous Chinese population. Our results might not be representative of the entire type 2 diabetic patient population. More large‐scale prospective studies should be carried out to confirm our findings.

In summary, our data showed that anemia was a common finding in Chinese patients with diabetes, particularly in those with albuminuria or renal impairment. Anemia was a risk factor for progression of renal diseases. However, when eGFR was included into the multivariate analysis, anemia was no longer an independent predictor of renal disease progression. The present study provided new information to the understanding of the association between anemia, diabetes and renal disease progression. More studies are required to elucidate the association among these three conditions.
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